home / stock / ghrs / ghrs news


GHRS News and Press, GH Research PLC From 04/02/24

Stock Information

Company Name: GH Research PLC
Stock Symbol: GHRS
Market: NASDAQ
Website: ghres.com

Menu

GHRS GHRS Quote GHRS Short GHRS News GHRS Articles GHRS Message Board
Get GHRS Alerts

News, Short Squeeze, Breakout and More Instantly...

GHRS - (GHRS) Proactive Strategies

2024-04-02 00:34:00 ET Stock Traders Daily has produced this trading report using a proprietary method.  This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...

GHRS - GH Research Reports Full Year 2023 Financial Results and Provides Business Updates

Phase 2b clinical trial of GH001 in patients with treatment-resistant depression on track for expected completion of double-blind phase in Q3 2024 Phase 2a clinical trial of GH001 in postpartum depression on track for expected completion in Q3 2024 Successfully completed Phase 1, dose-ran...

GHRS - (GHRS) Trading Advice

2024-02-20 16:40:00 ET Stock Traders Daily has produced this trading report using a proprietary method.  This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...

GHRS - Psychedelic stocks gain after FDA priority review for MDMA therapy

2024-02-12 12:13:32 ET More on ATAI, COMPASS Pathways, etc. Compass Pathways: Psilocybin Developer A Potentially Intriguing, Contrarian Play Mind Medicine: Positive MM-120 Data Leads To Other 2024 Catalysts De-Risking Psychedelics: Compass Pathways, Cybin And Atai ...

GHRS - GH Research Announces Grant of European Patent Covering all Mebufotenin (5-MeO-DMT) and Mebufotenin Salt Products For Use in the Treatment of Major Depressive Disorder and Treatment-Resistant Depression

DUBLIN, Ireland, Jan. 18, 2024 (GLOBE NEWSWIRE) -- GH Research PLC (Nasdaq: GHRS), a clinical-stage biopharmaceutical company dedicated to transforming the treatment of psychiatric and neurological disorders, today announced that it recently received a communication from the European Patent ...

GHRS - (GHRS) Technical Data

2024-01-08 13:24:00 ET Stock Traders Daily has produced this trading report using a proprietary method.  This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...

GHRS - CVAC, REE and NEON among mid-day movers

2023-12-19 12:49:04 ET Gainers: Panbela Therapeutics ( PBLA ) +54% . Singlepoint ( SING ) +41% . MedAvail Holdings ( MDVL ) +32% . REE Automotive Ltd ( REE ) +29% . Pulse Biosciences ( PLSE ) +28% . Neonode ( NEON ) +25...

GHRS - Gh Research Plc ($GHRS) Trading Report

2023-12-11 02:00:00 ET Stock Traders Daily has produced this trading report using a proprietary method.  This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...

GHRS - GH Research GAAP EPS of -$0.11

2023-11-10 08:02:21 ET More on GH Research Seeking Alpha’s Quant Rating on GH Research Historical earnings data for GH Research Financial information for GH Research For further details see: GH Research GAAP EPS of -$0.11

GHRS - GH Research Reports Third Quarter Financial Results and Provides Business Updates

DUBLIN, Ireland, Nov. 09, 2023 (GLOBE NEWSWIRE) -- GH Research PLC (Nasdaq: GHRS), a clinical-stage biopharmaceutical company dedicated to transforming the treatment of psychiatric and neurological disorders, today reported financial results for the third quarter ended September 30, 2023, and pro...

Previous 10 Next 10